Introduction
confusion, dyspepsia, spasticity, abnormal plasticity, pain, psychiatric, epilepsy syndromes Lennox-Gastaut, Idiopathic adult-onset blepharospasm, loss of central nervous system
DISORDERS, MULTIPLE SCLEROSIS, CHRONIC PAIN, FOCAL DYSTONIA, DRAVET SYNDROME
Idiopathic adult-onset blepharospasm (BPS), previously or also known as benign essential BPS, is an isolated, focal dystonia that causes an abnormal, episodic closure of the eyelids. The etiology is poorly understood, but studies suggest that loss of central nervous system (CNS) inhibition, abnormal plasticity, as well as atypical somatosensory discrimination all likely play a role.With legalization in many countries, cannabinoids have gained popularity within the general public and medical community. Currently, the US Food and Drug Administration (FDA) has approved Epidiolex, a purified cannabidiol (CBD), for use in treatment of resistant epilepsy syndromes Lennox-Gastaut and Dravet syndrome. Outside of the FDA approval, there have been numerous clinical trials looking at CBD potential in psychiatric disorders, chronic pain, and functional dyspepsia. Combinations of CBD and tetrahydrocannabinol (THC) have been given FDA-approval for the use of the nabiximols, which are combinations of CBD and tetrahydrocannabinol (THC), have been given FDA-approval for alleviating pain and spasticity in multiple sclerosis.However, cannabinoid application to BPS treatment has not been extensively studied by medical researchers, with only two published studies being noted. In 2017, Harrison et al.We note that there is a significant difference between CBD and THC, which is a common point of confusion to some patients and providers. CBD has low affinity for, and lack of functional activity at CB1 and CB2 receptors, whereas THC has a higher affinity for these receptorsDue to the high concentration of CBD receptors in the basal ganglia, as well as the muscle relaxant and anxiolytic effects of CBD,